Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta‐analysis of the liraglutide phase III clinical trial programme

@inproceedings{Montanya2016ImprovementIG,
  title={Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta‐analysis of the liraglutide phase III clinical trial programme},
  author={Eduard Montanya and Vivian Fonseca and Stephen Colagiuri and Lawrence Blonde and Morten Donsmark and Michael A Nauck},
  booktitle={Diabetes, obesity & metabolism},
  year={2016}
}
In the liraglutide clinical trial programme, liraglutide 1.2 and 1.8 mg were found to effectively lower glycated haemoglobin (HbA1c) in patients with type 2 diabetes (T2D). It is unknown whether baseline body mass index (BMI) is a predictor of change in HbA1c observed during a clinical trial with liraglutide or placebo treatment. The present meta-analysis of patient-level data, using pooled data from seven phase III trials [LEAD-1-6 and the liraglutide versus sitagliptin trial (LIRA-DPP-4)] for… CONTINUE READING
BETA
5
Twitter Mentions

Citations

Publications citing this paper.

References

Publications referenced by this paper.
SHOWING 1-10 OF 14 REFERENCES

The effect of liraglutide on A1c and body weight is largely dependent on diabetes duration

J Seufert, TS Bailey, CB Svendsen
  • Diabetes
  • 2013
VIEW 1 EXCERPT

Similar Papers

Loading similar papers…